Circulating microRNA profile unveils mechanisms of action of acitretin for psoriasis vulgaris

References

• Ouyang W. Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease. Cytokine Growth Factor Rev. 2010;21(6):435–441.
   PubMed Web of Science ®Google Scholar
• Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9–20.
   PubMed Web of Science ®Google Scholar
• Kolli SS, Amin SD, Pona A, et al. Psychosocial impact of psoriasis: a review for dermatology residents. Cutis. 2018;102(5S):21–25.
   PubMed Web of Science ®Google Scholar
• Pilon D, Teeple A, Zhdanava M, et al. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States. J Med Econ. 2019;22(2):196–203.
   PubMed Web of Science ®Google Scholar
• Cimmino MA. Epidemiology of psoriasis and psoriatic arthritis. Reumatismo. 2007;59(Suppl 1):19–24.
   PubMedGoogle Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–850.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Harel F, Krueger JG, et al. TNF-α antagonist and vascular inflammation in patients with psoriasis vulgaris: a randomized Placebo-controlled study. J Invest Dermatol. 2017;137(8):1638–1645.
   PubMed Web of Science ®Google Scholar
• Farahnik B, Beroukhim K, Abrouk M, et al. Brodalumab for the treatment of psoriasis: a review of Phase III trials. Dermatol Ther (Heidelb). 2016;6(2):111–124.
   PubMed Web of Science ®Google Scholar
• Iznardo H, Puig L. The safety of brodalumab for the treatment of psoriasis. Expert Opin Drug Saf. 2020;19(4):365–372.
   PubMed Web of Science ®Google Scholar
• Nast A, Boehncke WH, Mrowietz U, et al. Deutsche Dermatologische Gesellschaft (DDG), Berufsverband Deutscher Dermatologen (BVDD): S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges. 2012;10(Suppl 2):1–95.
   Web of Science ®Google Scholar
• Kostović K, Žužul K, Čeović R, et al. Psoriasis in the mature patient: therapeutic approach in the era of biologics. Clin Dermatol. 2018;36(2):222–230.
   PubMed Web of Science ®Google Scholar
• Neagu M, Constantin C, Cretoiu SM, et al. MiRNAs in the diagnosis and prognosis of skin cancer. Front Cell Dev Biol. 2020;8:71.
   PubMed Web of Science ®Google Scholar
• Sonkoly E, Wei T, Janson PC, et al. MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS One. 2007;2(7):e610.
   PubMed Web of Science ®Google Scholar
• Sonkoly E, Janson P, Majuri ML, et al. MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4. J Allergy Clin Immunol. 2010;126(3):581–589.
   PubMed Web of Science ®Google Scholar
• Solé C, Domingo S, Ferrer B, et al. MicroRNA expression profiling identifies miR-31 and miR-485-3p as regulators in the pathogenesis of discoid cutaneous Lupus. J Invest Dermatol. 2019;139(1):51–61.
   PubMed Web of Science ®Google Scholar
• Lee RC, Feinbaum RL, Ambros V, et al. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–854.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297.
   PubMed Web of Science ®Google Scholar
• Shang J, Sun S, Zhang L, et al. miR-211 alleviates ischaemia/reperfusion-induced kidney injury by targeting TGFβR2/TGF-β/SMAD3 pathway. Bioengineered. 2020;11(1):547–557.
   PubMed Web of Science ®Google Scholar
• Muljo SA, Ansel KM, Kanellopoulou C, et al. Aberrant T cell differentiation in the absence of Dicer. J Exp Med. 2005;202(2):261–269.
   PubMed Web of Science ®Google Scholar
• Baltimore D, Boldin MP, O’Connell RM, et al. MicroRNAs: new regulators of immune cell development and function. Nat Immunol. 2008;9(8):839–845.
   PubMed Web of Science ®Google Scholar
• Garo LP, Murugaiyan G. Contribution of MicroRNAs to autoimmune diseases. Cell Mol Life Sci. 2016;73(10):2041–2051.
   PubMed Web of Science ®Google Scholar
• Salvi V, Gianello V, Tiberio L, et al. Cytokine targeting by miRNAs in autoimmune diseases. Front Immunol. 2019;10:15.
   PubMed Web of Science ®Google Scholar
• Heegaard NHH, Carlsen AL, Skovgaard K, et al. Circulating Extracellular microRNAs in Systemic Autoimmunity. Exp Suppl. 2015;106:171–195.
   PubMedGoogle Scholar
• Keller A, Leidinger P, Bauer A, et al. Toward the blood-borne miRNome of human diseases. Nat Methods. 2011;8(10):841–843.
   PubMed Web of Science ®Google Scholar
• Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20(8):460–469.
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994.
   PubMed Web of Science ®Google Scholar
• Langmead B, Trapnell C, Pop M, et al. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10(3):R25.
   PubMed Web of Science ®Google Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.
   PubMed Web of Science ®Google Scholar
• Chou CH, Shrestha S, Yang CD, et al. miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 2018;46(D1):D296–d302.
   PubMed Web of Science ®Google Scholar
• Huang Da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Nakasa T, Miyaki S, et al. Expression of MicroRNA-146a in osteoarthritis cartilage. Arthritis Rheum. 2009;60(4):1035–1041.
   PubMed Web of Science ®Google Scholar
• Wang G, Tam LS, Li EK, et al. Serum and urinary cell-free MiR-146a and MiR-155 in patients with systemic lupus erythematosus. J Rheumatol. 2010;37(12):2516–2522.
   PubMed Web of Science ®Google Scholar
• Xia P, Fang X, Zhang ZH, et al. Dysregulation of miRNA146a versus IRAK1 induces IL-17 persistence in the psoriatic skin lesions. Immunol Lett. 2012;148(2):151–162.
   PubMed Web of Science ®Google Scholar
• Ichii O, Otsuka S, Sasaki N, et al. Altered expression of microRNA miR-146a correlates with the development of chronic renal inflammation. Kidney Int. 2012;81(3):280–292.
   PubMed Web of Science ®Google Scholar
• Turner ML, Schnorfeil FM, Brocker T. MicroRNAs regulate dendritic cell differentiation and function. J Immunol. 2011;187(8):3911–3917.
   PubMed Web of Science ®Google Scholar
• Taganov KD, Boldin MP, Chang KJ, et al. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006;103(33):12481–12486.
   PubMed Web of Science ®Google Scholar
• Lu LF, Boldin MP, Chaudhry A, et al. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell. 2010;142(6):914–929.
   PubMed Web of Science ®Google Scholar
• Niimoto T, Nakasa T, Ishikawa M, et al. MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. BMC Musculoskelet Disord. 2010;11(1):209.
   PubMedGoogle Scholar
• Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–390.
   PubMed Web of Science ®Google Scholar
• Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133(1):17–26.
   PubMed Web of Science ®Google Scholar
• Meisgen F, Xu N, Wei T, et al. MiR-21 is up-regulated in psoriasis and suppresses T cell apoptosis. Exp Dermatol. 2012;21(4):312–314.
   PubMed Web of Science ®Google Scholar
• Gu X, Nylander E, Coates PJ, et al. Effect of narrow-band ultraviolet B phototherapy on p63 and microRNA (miR-21 and miR-125b) expression in psoriatic epidermis. Acta Derm Venereol. 2011;91(4):392–397.
   PubMed Web of Science ®Google Scholar
• Agrawal U, Gupta M, Dube D, et al. Options and opportunities for clinical management and treatment of psoriasis. Crit Rev Ther Drug Carrier Syst. 2013;30(1):51–90.
   PubMed Web of Science ®Google Scholar
• Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31.e31–15.
   PubMed Web of Science ®Google Scholar
• Gordon K, Papp K, Poulin Y, et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012;66(2):241–251.
   PubMed Web of Science ®Google Scholar
• Guinea-Viniegra J, Jiménez M, Schonthaler HB, et al. Targeting miR-21 to treat psoriasis. Sci Transl Med. 2014;6(225):225re221.
   Web of Science ®Google Scholar
• Sato K, Takaishi M, Tokuoka S, et al. Involvement of TNF-α converting enzyme in the development of psoriasis-like lesions in a mouse model. PLoS One. 2014;9(11):e112408.
   PubMed Web of Science ®Google Scholar
• Zhong L, Xiao W, Wang F, et al. miR-21-5p inhibits neuropathic pain development via directly targeting C-C motif ligand 1 and tissue inhibitor of metalloproteinase-3. J Cell Biochem. 2019;120(10):16614–16623.
   PubMed Web of Science ®Google Scholar
• Wisniewska M, Goettig P, Maskos K, et al. Structural determinants of the ADAM inhibition by TIMP-3: crystal structure of the TACE-N-TIMP-3 complex. J Mol Biol. 2008;381(5):1307–1319.
   PubMed Web of Science ®Google Scholar
• Jiang M, Ma W, Gao Y, et al. IL-22-induced miR-122-5p promotes keratinocyte proliferation by targeting Sprouty2. Exp Dermatol. 2017;26(4):368–374.
   PubMed Web of Science ®Google Scholar
• Ni X, Lai Y. Keratinocyte: a trigger or an executor of psoriasis? J Leukoc Biol. 2020;108(2):485–491.
   PubMed Web of Science ®Google Scholar
• Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008;28(4):454–467.
   PubMed Web of Science ®Google Scholar
• Okur MN, Russo A, O’Bryan JP. Receptor tyrosine kinase ubiquitylation involves the dynamic regulation of Cbl-Spry2 by intersectin 1 and the Shp2 tyrosine phosphatase. Mol Cell Biol. 2014;34(2):271–279.
   PubMed Web of Science ®Google Scholar
• Gross I, Bassit B, Benezra M, et al. Mammalian sprouty proteins inhibit cell growth and differentiation by preventing ras activation. J Biol Chem. 2001;276(49):46460–46468.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Ibe M, Nakamura S, et al. Extracellular regulated kinase and c-Jun N-terminal kinase are activated in psoriatic involved epidermis. J Dermatol Sci. 2002;30(2):94–99.
   PubMed Web of Science ®Google Scholar
• Yu XJ, Li CY, Dai HY, et al. Expression and localization of the activated mitogen-activated protein kinase in lesional psoriatic skin. Exp Mol Pathol. 2007;83(3):413–418.
   PubMed Web of Science ®Google Scholar